- Home
- VYGR vs LEGT Comparison
VYGR vs LEGT Comparison
Compare VYGR & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYGR
- LEGT
- Stock Information
- Founded
- VYGR 2013
- LEGT 2023
- Country
- VYGR United States
- LEGT United States
- Employees
- VYGR N/A
- LEGT N/A
- Industry
- VYGR Biotechnology: Pharmaceutical Preparations
- LEGT
- Sector
- VYGR Health Care
- LEGT
- Exchange
- VYGR Nasdaq
- LEGT Nasdaq
- Market Cap
- VYGR 231.9M
- LEGT 276.8M
- IPO Year
- VYGR 2015
- LEGT 2024
- Fundamental
- Price
- VYGR $4.21
- LEGT $10.77
- Analyst Decision
- VYGR Strong Buy
- LEGT
- Analyst Count
- VYGR 8
- LEGT 0
- Target Price
- VYGR $16.71
- LEGT N/A
- AVG Volume (30 Days)
- VYGR 635.7K
- LEGT 21.9K
- Earning Date
- VYGR 11-11-2025
- LEGT 01-01-0001
- Dividend Yield
- VYGR N/A
- LEGT N/A
- EPS Growth
- VYGR N/A
- LEGT N/A
- EPS
- VYGR N/A
- LEGT 0.35
- Revenue
- VYGR $42,580,000.00
- LEGT N/A
- Revenue This Year
- VYGR N/A
- LEGT N/A
- Revenue Next Year
- VYGR $107.07
- LEGT N/A
- P/E Ratio
- VYGR N/A
- LEGT $30.68
- Revenue Growth
- VYGR N/A
- LEGT N/A
- 52 Week Low
- VYGR $2.65
- LEGT $10.18
- 52 Week High
- VYGR $8.28
- LEGT $10.86
- Technical
- Relative Strength Index (RSI)
- VYGR 62.64
- LEGT 61.22
- Support Level
- VYGR $3.91
- LEGT $10.72
- Resistance Level
- VYGR $4.51
- LEGT $10.74
- Average True Range (ATR)
- VYGR 0.27
- LEGT 0.01
- MACD
- VYGR 0.05
- LEGT 0.00
- Stochastic Oscillator
- VYGR 74.79
- LEGT 83.33
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.